Presentation is loading. Please wait.

Presentation is loading. Please wait.

Poorly cytotoxic terminally differentiated CD56negCD16pos NK cells accumulate in Kenyan children with Burkitt lymphomas by Catherine S. Forconi, Cormac.

Published byあかり つちかね Modified over 5 years ago

Similar presentations

Presentation on theme: "Poorly cytotoxic terminally differentiated CD56negCD16pos NK cells accumulate in Kenyan children with Burkitt lymphomas by Catherine S. Forconi, Cormac."— Presentation transcript:

1 Poorly cytotoxic terminally differentiated CD56negCD16pos NK cells accumulate in Kenyan children with Burkitt lymphomas by Catherine S. Forconi, Cormac P. Cosgrove, Pryia Saikumar-Lakshmi, Christina E. Nixon, Joslyn Foley, John Michael Ong’echa, Juliana A. Otieno, Galit Alter, Christian Münz, and Ann M. Moormann BloodAdv Volume 2(10): May 22, 2018 © 2018 by The American Society of Hematology

2 Catherine S. Forconi et al. Blood Adv 2018;2:1101-1114
© 2018 by The American Society of Hematology

3 Characterization of NK cell subsets in Kenyan children.
Characterization of NK cell subsets in Kenyan children. Children were categorized by malaria and EBV exposure, as well as eBL diagnosis: Nandi (EBVlow/malarialow; n = 10), Kisumu (EBVhigh/malariahigh; n = 10), and eBL patients (n = 14) with no/low EBV and high EBV loads. (A) The percentage of NK cells within the circulating lymphocytes was defined as the number of NK cells (CD56pos and/or CD16pos)/total number of live lymphocytes. (B) Five NK cell subsets were defined by CD56 and CD16 expression levels: CD56brightCD16neg, CD56brightCD16pos, CD56dimCD16neg, CD56dimCD16pos, and CD56negCD16pos. (C) Percentages of NK cell subsets for each group of children within our study. (D) Representative proportions of NK cell subsets in different groups of children. Data in panels A and C are mean ± standard deviation (SD). *P < .05, **P < .01, ***P < .001. Catherine S. Forconi et al. Blood Adv 2018;2: © 2018 by The American Society of Hematology

4 Comparison of KIR and perforin expression by different NK cell subsets for Nandi, Kisumu, and eBL children. Comparison of KIR and perforin expression by different NK cell subsets for Nandi, Kisumu, and eBL children. Comparison of KIR2DL1S1 (A), KIR2DL1S5 (B), KIR2DL2 (C), KIR2DL3 (D), and KIR3DL1 (E) among the different NK cell subsets: CD56brightCD16neg (1), CD56brightCD16pos (2), CD56dimCD16pos (3), and CD56negCD16pos (4). (F) Expression of KIR3DL1 on CD56negCD16pos NK cells among Nandi, Kisumu, and eBL children. For all KIRs, Nandi, n = 7; Kisumu, n = 5; and BL, n = 10. (G) Perforin expression by NK cell subsets: CD56brightCD16neg (1), CD56brightCD16pos (2), CD56dimCD16pos (3), and CD56negCD16pos (4) (Nandi, n = 4; Kisumu, n = 5; eBL, n = 9). (H) Color code used for data. Data are mean ± SD. *P < .05, **P < .01, ***P < .001, ****P < n.s., not significant. Catherine S. Forconi et al. Blood Adv 2018;2: © 2018 by The American Society of Hematology

5 Expression of NKp30, NKp46, and CD161 consistent with an adaptive NK cell phenotype.
Expression of NKp30, NKp46, and CD161 consistent with an adaptive NK cell phenotype. NK cell subsets, including CD56brightCD16neg (1), CD56brightCD16pos (2), CD56dimCD16pos (3), and CD56negCD16pos (4), were evaluated for each group of children: Nandi (EBVlow/malarialow), Kisumu (EBVhigh/malariahigh), and eBL patients with low EBV and high EBV load. Comparison of NKp30 (A) and NKp46 (B) expression on the different NK cell subsets across all study groups. NKp30 (C) and NKp46 (D) expression on CD56negCD16pos NK cell subsets across study groups. Nandi, n = 10; Kisumu, n = 8; and BL, n = 11 for NCRs. (E) Comparison of CD161 on the different NK cell subsets across all study groups. (F) CD161 expression on the CD56negCD16pos NK cell subset across study groups. Nandi, n = 8; Kisumu, n = 8; and BL, n = 11 for CD161 expression. Data are mean ± SD. *P < .05, **P < .01, ***P < .001. Catherine S. Forconi et al. Blood Adv 2018;2: © 2018 by The American Society of Hematology

6 Expression of the NKG2D and 2B4 coactivation receptors on NK cell subsets from Nandi, Kisumu, and eBL children. Expression of the NKG2D and 2B4 coactivation receptors on NK cell subsets from Nandi, Kisumu, and eBL children. NK cell subsets, including CD56brightCD16neg (1), CD56brightCD16pos (2), CD56dimCD16pos (3), and CD56negCD16pos (4), were evaluated for each group of children: Nandi (EBVlow/malarialow), Kisumu (EBVhigh/malariahigh), and BL with low EBV and BL with high EBV. NKG2D expression by (A) NK cell subset representation (A) and by linear representation (B) across study groups (Nandi, n = 8; Kisumu, n = 6; and BL, n = 11). 2B4 expression by NK cells subset representation (C) and by linear representation (D) across study groups (Nandi, n = 6; Kisumu, n = 4; and BL, n = 10). Data are mean ± SD. *P < .05, **P < .01, ***P < .001. Catherine S. Forconi et al. Blood Adv 2018;2: © 2018 by The American Society of Hematology

7 Absence of the CD57/NKG2C NK cell phenotype otherwise found in HCMV-EBV coinfection.
Absence of the CD57/NKG2C NK cell phenotype otherwise found in HCMV-EBV coinfection. NK cell subsets, including CD56brightCD16neg (1), CD56brightCD16pos (2), CD56dimCD16pos (3), and CD56negCD16pos (4), were evaluated for each group of children: Nandi (EBVlow/malarialow), Kisumu (EBVhigh/malariahigh), and eBL patients with no/low EBV and high EBV loads. (A) Comparison of CD57 among the different NK cell subsets across study groups. (B) CD57 expression on the CD56negCD16pos NK cell subset across study groups. (C) Comparison of NKG2C expression among different NK cell subsets across groups of children. (D) NKG2C expression on the CD56negCD16pos NK cell subset across study groups. (E) Median fluorescence intensity (MFI) of antibody titers against CMV. (F) Coexpression of CD57 and NKG2C on CD56dimCD16pos and CD56negCD16pos NK cells. (G) CD57posNKG2Cpos expression between CD56dimCD16pos and CD56negCD16pos subsets across study groups. For CD57, Nandi, n = 8; Kisumu, n = 6, and BL, n = 11. For NKG2C, Nandi, n = 7; Kisumu, n = 5; and BL, n = 11. Data are mean ± SD. *P < .05, **P < .01, ***P < .001. Catherine S. Forconi et al. Blood Adv 2018;2: © 2018 by The American Society of Hematology

8 MIP-1β production and degranulation of CD56neg CD16pos NK cell subset after K562 cell stimulation.
MIP-1β production and degranulation of CD56negCD16posNK cell subset after K562 cell stimulation. PBMCs from healthy children (Nandi and Kisumu; n = 7) and eBL children (n = 7) were stimulated with K562 cells in a functional in vitro killing assay. NK cell subsets were defined by CD56 and CD16 expression levels. (A) Percentage of MIP-1βpos NK cells in each subset, with and without stimulation. (B) Percentage of TNF-αpos NK cells in each subset, with and without stimulation. (C) Comparison of MIP-1β, TNF-α, CD107a, and IFN-γ positive cells after K562 cell stimulation between the CD56dimCD16pos and CD56negCD16pos NK cell subsets. The Wilcoxon test was used for related data, and Mann-Whitney U test was used for nonrelated data. Data are mean ± SD. *P < .05. Catherine S. Forconi et al. Blood Adv 2018;2: © 2018 by The American Society of Hematology

9 Resolution of the CD56neg CD16pos subset from eBL children after chemotherapy.
Resolution of the CD56negCD16possubset from eBL children after chemotherapy. NK cell subsets were defined by CD56 and CD16 expression. The first time point was before chemotherapy, and the second and third time points were 3 and 9 months, respectively, after diagnosis (during remission). (A) Changes in the percentage of NK cells were defined as the number of NK cells (CD56pos and/or CD16pos)/total number of live lymphocytes. (B) Changes in the percentage of CD56negCD16pos NK cells at each time point for 2 eBL patients. (C) Cytograms for the 3 time points for patient “BL1.” Changes in activation (D) and NCR (E) markers over time for both eBL children (“BL1” and “BL2”) for CD56negCD16pos NK cells. (F) Plots of NKp30/NKp46, NKp30/2B4, and NKp46/2B4 coexpression for CD56negCD16pos NK cells from an eBL1 patient during the course of treatment, as well as for 3 healthy Nandi children. Catherine S. Forconi et al. Blood Adv 2018;2: © 2018 by The American Society of Hematology

Download ppt "Poorly cytotoxic terminally differentiated CD56negCD16pos NK cells accumulate in Kenyan children with Burkitt lymphomas by Catherine S. Forconi, Cormac."

Similar presentations

Volume 2, Issue 10, Pages (October 2015)

Volume 2, Issue 10, Pages (October 2015)
WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell–depleted hematopoietic stem cell transplantation and.

WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell–depleted hematopoietic stem cell transplantation and.
Supplementary Figure 2 Supplementary Figure 2. White blood cell differential count White blood cell (WBC) differential counts were analyzed from patients.

Supplementary Figure 2 Supplementary Figure 2. White blood cell differential count White blood cell (WBC) differential counts were analyzed from patients.
Gene transfer into hematopoietic stem cells reduces HLH manifestations in a murine model of Munc13-4 deficiency by Tayebeh Soheili, Amandine Durand, Fernando.

Gene transfer into hematopoietic stem cells reduces HLH manifestations in a murine model of Munc13-4 deficiency by Tayebeh Soheili, Amandine Durand, Fernando.
Selective expansion of polyfunctional pathogen-specific CD4+ T cells in HIV-1–infected patients with immune reconstitution inflammatory syndrome by Yolanda.

Selective expansion of polyfunctional pathogen-specific CD4+ T cells in HIV-1–infected patients with immune reconstitution inflammatory syndrome by Yolanda.
by Venetia Bigley, Laura E. Spence, and Matthew Collin

by Venetia Bigley, Laura E. Spence, and Matthew Collin
CD56+/CD16− Natural Killer cells expressing the inflammatory protease granzyme A are enriched in synovial fluid from patients with osteoarthritis  P.

CD56+/CD16− Natural Killer cells expressing the inflammatory protease granzyme A are enriched in synovial fluid from patients with osteoarthritis  P.
Thymocyte Fas Expression Is Dysregulated in Myasthenia Gravis Patients With Anti-Acetylcholine Receptor Antibody by Nathalie Moulian, Jocelyne Bidault,

Thymocyte Fas Expression Is Dysregulated in Myasthenia Gravis Patients With Anti-Acetylcholine Receptor Antibody by Nathalie Moulian, Jocelyne Bidault,
Expansion of NKG2A−LIR1− Natural Killer Cells in HLA-Matched, Killer Cell Immunoglobulin-Like Receptors/HLA-Ligand Mismatched Patients following Hematopoietic.

Expansion of NKG2A−LIR1− Natural Killer Cells in HLA-Matched, Killer Cell Immunoglobulin-Like Receptors/HLA-Ligand Mismatched Patients following Hematopoietic.
Impaired function of human T-lymphotropic virus type 1 (HTLV-1)–specific CD8+ T cells in HTLV-1–associated neurologic disease by Amir H. Sabouri, Koichiro.

Impaired function of human T-lymphotropic virus type 1 (HTLV-1)–specific CD8+ T cells in HTLV-1–associated neurologic disease by Amir H. Sabouri, Koichiro.
Long-term expansion of effector/memory Vδ2− γδ T cells is a specific blood signature of CMV infection by Vincent Pitard, David Roumanes, Xavier Lafarge,

Long-term expansion of effector/memory Vδ2− γδ T cells is a specific blood signature of CMV infection by Vincent Pitard, David Roumanes, Xavier Lafarge,
Human NK cell development in NOD/SCID mice receiving grafts of cord blood CD34+ cells by Christian P. Kalberer, Uwe Siegler, and Aleksandra Wodnar-Filipowicz.

Human NK cell development in NOD/SCID mice receiving grafts of cord blood CD34+ cells by Christian P. Kalberer, Uwe Siegler, and Aleksandra Wodnar-Filipowicz.
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation by Ann M.

Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation by Ann M.
Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion by Yenan T. Bryceson, Michael E. March, Hans-Gustaf.

Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion by Yenan T. Bryceson, Michael E. March, Hans-Gustaf.
Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role.

Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role.
Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States by Jeffrey I. Cohen, Elaine S. Jaffe,

Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States by Jeffrey I. Cohen, Elaine S. Jaffe,
Interleukins 12 and 15 induce cytotoxicity and early NK-cell differentiation in type 3 innate lymphoid cells by Ana Raykova, Paolo Carrega, Frank M. Lehmann,

Interleukins 12 and 15 induce cytotoxicity and early NK-cell differentiation in type 3 innate lymphoid cells by Ana Raykova, Paolo Carrega, Frank M. Lehmann,
Volume 137, Issue 3, Pages e7 (September 2009)

Volume 137, Issue 3, Pages e7 (September 2009)
Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen–specific CD8+ T-cell function in Hodgkin.

Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen–specific CD8+ T-cell function in Hodgkin.
Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kδ inhibitors and VIP antagonists by Christopher T.

Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kδ inhibitors and VIP antagonists by Christopher T.

Similar presentations

Ads by Google